CoChat

MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study

Open access
Schuman-Olivier, Zev, Borodovsky, Jacob T., Steinkamp, Jackson, Munir, Qays, Butler, Kyle, Greene, Mary Ann, Goldblatt, Jonah, Xie, Hai Yi, Marsch, Lisa A. · 2018 · Addiction Science & Clinical Practice

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

BACKGROUND: While buprenorphine/naloxone (B/N) is approved for opioid use disorder treatment, effective delivery of B/N comes with significant challenges. Most notably, many patients do not take medication daily as prescribed; this non-adherence worsens treatment outcomes, increases healthcare costs, and leads to persistent worries of diversion among providers and policymakers. The present study examines the feasibility, usability, and acceptability of MySafeRx-a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing designed to address the challenges of office-based opioid treatment (OBOT) with B/N. METHODS: The MySafeRx platform integrates electronic pill dispensers, text-messaging, and videoconferencing to provide supervised self-administration of medication and daily motivational coaching through an Android app interface. High-risk early adults (18-39 years old) who were enrolled in OBOT with B/N and had documented illicit opioid use in the past month during opioid agonist therapy (n = 12) participated in a 28-day single-arm observational study of the MySafeRx platform in addition to standard care. RESULTS: Two-thirds of participants who completed the study achieved an average of > 5 days per week of supervised B/N self-administration. Visual confirmation of medication adherence was demonstrated for an average of 72% of study days among all participants. All participants achieved platform technical proficiency within 60 min, reporting good levels of usability and acceptability. Illicit opioid abstinence rates confirmed by urine toxicology increased by 53% during MySafeRx but fell 43% within 3 weeks post-intervention. CONCLUSION: The MySafeRx medication adherence and remote coaching mobile platform is acceptable and can be feasibly implemented in real-world opioid use disorder treatment settings during high-risk periods (i.e., initial stabilization, after illicit opioid lapse), resulting in reduced illicit opioid use; however, the effect did not last after intervention completion, suggesting longer duration or extended taper of program may be needed. ClinicalTrials.Gov NCT02942199 10/24/16 https://clinicaltrials.gov/ct2/show/NCT02942199.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13722-018-0122-4

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 MedicaSafe pill dispenser
Fig. 1 MedicaSafe pill dispenserCC BY · PubMed Central
Fig. 2 MysafeRx mobile recovery program
Fig. 2 MysafeRx mobile recovery programCC BY · PubMed Central
Fig. 3 Consort diagram
Fig. 3 Consort diagramCC BY · PubMed Central
Fig. 4 Frequency of illicit opioid abstinence during and after MySafeRx (based on weekly toxicology)
Fig. 4 Frequency of illicit opioid abstinence during and after MySafeRx (based on weekly toxicology)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Research works printed but not linked: 4

  1. Center for Substance Abuse Treatment, Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40, 2004, Substance Abuse and Mental Health Services Administration: Rockville, MD. 22514846
  2. Schuman-Olivier Z et al. MySafeRx: an integrated mobile platform for buprenorphine adherence. In: American academy of addiction psychiatry (AAAP) 27th annual meeting and symposium 2016. Bonita Springs: Wiley/Blackwell (10.1111).
  3. First MB et al. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition. Vol. SCID-I/P. 2002, New York: Biometrics Research, New York State Psychiatric Institute.
  4. Schuman-Olivier Z et al. Feasibility for ActiWatch score (TM) for recording skills practice and conducting ecological momentary assessment in a RCT of mindfulness training vs. cognitive-behavioral therapy for tobacco smoking cessation. In: Poster presentation, international symposium on contemplative studies; 2012.

Cited by

See all 44

Metadata

Authors
Schuman-Olivier, Z., Borodovsky, J. T., Steinkamp, J., Munir, Q., Butler, K., Greene, M. A., Goldblatt, J., Xie, H. Y., & Marsch, L. A.
Affiliations
  • Dartmouth College (US)
  • Boston University (US)
  • Tufts University (US)
Venue
Addiction Science & Clinical Practice
Published
2018-09-24
Volume
13
Issue
1
Pages
21-21
ISSN
  • 1940-0632 (ISSN-L)
  • 1940-0640
OpenAlex
W2891084063
Cited by
44
References
70
Citations by year
2026: 5 · 2025: 5 · 2024: 2 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 8 · 2019: 2 · 2018: 1
FWCI
4.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Addiction Science & Clinical Practice (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institute on Drug Abuse (P30DA029926, R34DA040086, R43DA033702)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Keywords
buprenorphine/naloxone, opioid use disorder, medication adherence, motivational coaching, mobile health, office-based opioid treatment, opioid substitution therapy, illicit opioid use, opioid diversion, early adults, urine toxicology, feasibility and acceptability
MeSH terms
Smartphone, Buprenorphine, Naloxone Drug Combination, Mentoring, Adolescent, Adult, Female, Humans, Male, Motivation, Opioid-Related Disorders, Pilot Projects, Reminder Systems, Patient Satisfaction, Videoconferencing, Medication Adherence, Young Adult, Text Messaging, Mobile Applications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study. https://app.cochat.ai/papers/10.1186/s13722-018-0122-4
The paper
Schuman-Olivier, Z., Borodovsky, J. T., Steinkamp, J., Munir, Q., Butler, K., Greene, M. A., Goldblatt, J., Xie, H. Y., & Marsch, L. A. (2018). MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study. Addiction Science & Clinical Practice. https://doi.org/10.1186/s13722-018-0122-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.